BACKGROUND: In this study, we aimed to assess the efficacy and safety of balloon pulmonary angioplasty (BPA) in patients with technically inoperable distal-type chronic thromboembolic pulmonary hypertension (d-CTEPH) and technically operable proximal-type disease (p-CTEPH) by analyzing the results of BPA treatment in two collaborating CTEPH referral centers. METHODS AND RESULTS: We assessed hemodynamic results, functional efficacy, complication and survival rate after BPA treatment in 70 CTEPH patients (median age 64 years; (interquartile range (IQR): 52-73 years)), of whom 16 (median age 73 years; (QR 62-82 years)) were in the p-CTEPH subgroup. Altogether, 377 BPA procedures were performed, resulting in significant (p < 0.001) improvement in mean pulmonary artery pressure (mPAP 48.6 ± 10 vs. 31.3 ± 8.6 mmHg), pulmonary vascular resistance (694 ± 296 vs. 333 ± 162 dynes*s*cm-5), six-minute walk test (365 ± 142 vs. 433 ± 120 metres) and N-terminal pro B-type natriuretic peptide (1307 (510-3294) vs. 206 (83-531) pg/mL). The rate of improvement did not differ between the sub-groups. Lung injury episodes and severe hemoptysis were similarly infrequent in d-CTEPH and p-CTEPH (6.4% vs. 5%; p = 0.55 and 1.0% vs. 2.5; p = 0.24, respectively). There was no significant difference between the sub-groups regarding survival (p = 0.53 by log-rank test). CONCLUSION: BPA may be beneficial in patients with p-CTEPH who cannot undergo pulmonary endarterectomy (PEA). Larger long-term studies are needed to better define the efficacy, safety, and optimal BPA procedural standards in this population.
BACKGROUND: In this study, we aimed to assess the efficacy and safety of balloon pulmonary angioplasty (BPA) in patients with technically inoperable distal-type chronic thromboembolic pulmonary hypertension (d-CTEPH) and technically operable proximal-type disease (p-CTEPH) by analyzing the results of BPA treatment in two collaborating CTEPH referral centers. METHODS AND RESULTS: We assessed hemodynamic results, functional efficacy, complication and survival rate after BPA treatment in 70 CTEPHpatients (median age 64 years; (interquartile range (IQR): 52-73 years)), of whom 16 (median age 73 years; (QR 62-82 years)) were in the p-CTEPH subgroup. Altogether, 377 BPA procedures were performed, resulting in significant (p < 0.001) improvement in mean pulmonary artery pressure (mPAP 48.6 ± 10 vs. 31.3 ± 8.6 mmHg), pulmonary vascular resistance (694 ± 296 vs. 333 ± 162 dynes*s*cm-5), six-minute walk test (365 ± 142 vs. 433 ± 120 metres) and N-terminal pro B-type natriuretic peptide (1307 (510-3294) vs. 206 (83-531) pg/mL). The rate of improvement did not differ between the sub-groups. Lung injury episodes and severe hemoptysis were similarly infrequent in d-CTEPH and p-CTEPH (6.4% vs. 5%; p = 0.55 and 1.0% vs. 2.5; p = 0.24, respectively). There was no significant difference between the sub-groups regarding survival (p = 0.53 by log-rank test). CONCLUSION:BPA may be beneficial in patients with p-CTEPH who cannot undergo pulmonary endarterectomy (PEA). Larger long-term studies are needed to better define the efficacy, safety, and optimal BPA procedural standards in this population.
Authors: Nazzareno Galiè; Marc Humbert; Jean-Luc Vachiery; Simon Gibbs; Irene Lang; Adam Torbicki; Gérald Simonneau; Andrew Peacock; Anton Vonk Noordegraaf; Maurice Beghetti; Ardeschir Ghofrani; Miguel Angel Gomez Sanchez; Georg Hansmann; Walter Klepetko; Patrizio Lancellotti; Marco Matucci; Theresa McDonagh; Luc A Pierard; Pedro T Trindade; Maurizio Zompatori; Marius Hoeper Journal: Kardiol Pol Date: 2015 Impact factor: 3.108
Authors: Nazzareno Galiè; Marc Humbert; Jean-Luc Vachiery; Simon Gibbs; Irene Lang; Adam Torbicki; Gérald Simonneau; Andrew Peacock; Anton Vonk Noordegraaf; Maurice Beghetti; Ardeschir Ghofrani; Miguel Angel Gomez Sanchez; Georg Hansmann; Walter Klepetko; Patrizio Lancellotti; Marco Matucci; Theresa McDonagh; Luc A Pierard; Pedro T Trindade; Maurizio Zompatori; Marius Hoeper Journal: Eur Respir J Date: 2015-08-29 Impact factor: 16.671
Authors: Eckhard Mayer; David Jenkins; Jaroslav Lindner; Andrea D'Armini; Jaap Kloek; Bart Meyns; Lars Bo Ilkjaer; Walter Klepetko; Marion Delcroix; Irene Lang; Joanna Pepke-Zaba; Gerald Simonneau; Philippe Dartevelle Journal: J Thorac Cardiovasc Surg Date: 2011-03 Impact factor: 5.209
Authors: Stuart W Jamieson; David P Kapelanski; Naohide Sakakibara; Gerard R Manecke; Patricia A Thistlethwaite; Kim M Kerr; Richard N Channick; Peter F Fedullo; William R Auger Journal: Ann Thorac Surg Date: 2003-11 Impact factor: 4.330
Authors: Szymon Darocha; Marta Banaszkiewicz; Arkadiusz Pietrasik; Anna Siennicka; Mateusz Piorunek; Emilia Grochowska; Michał Piłka; Anna Dobosiewicz; Michał Florczyk; Radosław Pietura; Adam Torbicki; Marcin Kurzyna Journal: Cardiorenal Med Date: 2019-09-17 Impact factor: 2.041
Authors: Sylwia Sławek-Szmyt; Aleksander Araszkiewicz; Stanisław Jankiewicz; Marek Grygier; Tatiana Mularek-Kubzdela; Maciej Lesiak Journal: J Clin Med Date: 2022-05-12 Impact factor: 4.964
Authors: Szymon Darocha; Paweł Kurzyna; Marta Banaszkiewicz-Cyganik; Piotr Kędzierski; Michał Florczyk; Arkadiusz Pietrasik; Dariusz Zieliński; Andrzej Biederman; Adam Torbicki; Marcin Kurzyna Journal: Pulm Circ Date: 2022-05-27 Impact factor: 2.886
Authors: Sylwia Sławek-Szmyt; Aleksander Araszkiewicz; Stanisław Jankiewicz; Anna Smukowska-Gorynia; Marek Grygier; Magdalena Janus; Maciej Lesiak; Tatiana Mularek-Kubzdela Journal: J Clin Med Date: 2022-01-26 Impact factor: 4.241
Authors: Marta Banaszkiewicz; Aleksandra Gąsecka; Szymon Darocha; Michał Florczyk; Arkadiusz Pietrasik; Piotr Kędzierski; Michał Piłka; Adam Torbicki; Marcin Kurzyna Journal: J Clin Med Date: 2022-01-13 Impact factor: 4.241